Brief: RhoVac Reports Positive Results From Follow-Up Of Phase I/II Clinical Study

Chosa Oncology AB

04/07/2019 10:33

July 4 (Reuters) - RhoVac AB  RHOVAC.TE :
    * RHOVAC'S REPORTS POSITIVE RESULTS FROM THE 12 MONTHS
FOLLOW-UP
OF THE COMPANY'S PHASE I/II CLINICAL STUDY
    * OVER-ALL CONCLUSION OF RHOVAC-001 STUDY INCLUDING
LONG-TERM
FOLLOW-UP PHASE IS THAT THAT TREATMENT WITH RV001 IS SAFE AND
WELL TOLERATED BY PROSTATE CANCER PATIENTS
    * OF 18 PATIENTS SHOWING SIGNIFICANT TREATMENT RELATED
IMMUNOLOGICAL RESPONSE AT COMPLETION OF TREATMENT, ALL 18
PATIENTS STILL SHOWED SIGNIFICANT RESPONSE AT 3-, 6- AND
9-MONTHS FOLLOW-UP
    * FOLLOW-UP DATA CONFIRMS THAT OUR PRODUCT HAS A VERY GOOD
SAFETY
PROFILE AND IS WELL TOLERATED BY PROSTATE CANCER PATIENTS

Source text for Eikon:  ID:nWkr6K1dQB 
Further company coverage:  RHOVAC.TE 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))